_Alba Schmahl
Alba holds a MSc in Oncology from University College London and a biochemistry BSc degree from the Technical University of Munich. Her academic training provided her with a strong foundation in molecular and biochemical processes, which she further specialized in the field of oncology.
Prior to joining LifeLink Ventures, she gained experience across both academic and industry settings. She worked as an Associate Scientist in the Liver Disease Department at Novo Nordisk, where she developed an understanding of drug development in an industrial setting. In previous years, her research in CAR-T cell therapies led to a publication on engineering de novo CAR-T cell binders using generative AI.
Driven by a strong interest in entrepreneurship and the translational potential for scientific innovation, Alba is motivated to contribute to the scientific due diligence and investment evaluation at LifeLink Ventures.